Pharmacologic prevention of venous thromboembolism in obese patients

Journal of Thrombosis and Thrombolysis

Volumn 36, Issue 3, 2013, Pages 247-257

  Bakirhan, K ^a,b   Strakhan, M ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

Anticoagulation; DVT; Obesity; PE; Thromboembolism prophylaxis

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; DABIGATRAN ETEXILATE; DALTEPARIN; ENOXAPARIN; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADTROPARIN; PLACEBO; RIVAROXABAN; TINZAPARIN; UNCLASSIFIED DRUG;

ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; BLEEDING; BODY COMPOSITION; BODY WEIGHT; CONTINUOUS INFUSION; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; HIGH RISK POPULATION; HUMAN; LUNG EMBOLISM; OBESITY; PATHOGENESIS; PRIORITY JOURNAL; RISK FACTOR; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; DOUBLE-BLIND METHOD; FACTOR XA; HUMANS; OBESITY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; VENOUS THROMBOEMBOLISM;

EID: 84884815160     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-012-0844-1     Document Type: Article

References (76)

1. Gould MK, Garcia DA, Wren SM, Karanicolas PJ, Arcelus JI, Heit JA, Samama CM, American College of Chest P (2012) Prevention of VTE in nonorthopedic surgical patients: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141:e227S-e277S. doi: 10.1378/chest.11-2297
2. Spyropoulos AC, Mahan C (2009) Venous thromboembolism prophylaxis in the medical patient: Controversies and perspectives. Am J Med 122(12):1077-1084. doi: 10.1016/j.amjmed.2009.04.027
3. Anderson FA, Jr., Wheeler HB (1992) Physician practices in the management of venous thromboembolism: A community-wide survey. Journal of vascular surgery: official publication, the Society for Vascular Surgery [and] International Society for Cardiovascular Surgery, North American Chapter 16 (5):707-714
4. Flegal KM, Carroll MD, Ogden CL, Curtin LR (2010) Prevalence and trends in obesity among US adults, 1999-2008. JAMA 303(3):235-241. doi: 10.1001/jama.2009.2014
5. Kabrhel C, Varraso R, Goldhaber SZ, Rimm EB, Camargo CA (2009) Prospective study of BMI and the risk of pulmonary embolism in women. Obesity 17(11):2040-2046. doi: 10.1038/oby.2009.92
6. Blaszyk H, Bjornsson J (2000) Factor V leiden and morbid obesity in fatal postoperative pulmonary embolism. Arch Surg 135(12):1410-1413
7. Stein PD, Beemath A, Olson RE (2005) Obesity as a risk factor in venous thromboembolism. Am J Med 118(9):978-980. doi: 10.1016/j.amjmed.2005.03.012
8. Heit JA (2002) Venous thromboembolism epidemiology: Implications for prevention and management. Semin Thromb Hemost 28(SUPPL. 2):3-13. doi: 10.1055/s-2002-32312
9. Eichinger S, Hron G, Bialonczyk C, Hirschl M, Minar E, Wagner O, Heinze G, Kyrle PA (2008) Overweight, obesity, and the risk of recurrent venous thromboembolism. Arch Intern Med 168(15):1678-1683. doi: 10.1001/archinte.168. 15.1678
10. Heit JA, Silverstein MD, Mohr DN, Petterson TM, Lohse CM, O'Fallon WM, Melton LJ 3rd (2001) The epidemiology of venous thromboembolism in the community. Thromb Haemost 86(1):452-463
11. Anderson FA Jr, Spencer FA (2003) Risk factors for venous thromboembolism. Circulation 107(23 SUPPL. 1):I9-I16. doi: 10.1161/01.CIR. 0000078469.07362.E6
12. Eriksson S, Backman L, Ljungstrom KG (1997) The incidence of clinical postoperative thrombosis after gastric surgery for obesity during 16 years. Obes surg 7(4):332-335. doi: 10.1381/096089297765555575 Discussion 336
13. Belch JJ, Lowe GD, Ward AG, Forbes CD, Prentice CR (1981) Prevention of deep vein thrombosis in medical patients by low-dose heparin. Scott Med J 26(2):115-117
14. Samama MM, Cohen AT, Darmon JY, Desjardins L, Eldor A, Janbon C, Leizorovicz A, Nguyen H, Olsson CG, Turpie AG, Weisslinger N (1999) A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in medical patients with enoxaparin study group. N Engl J Med 341(11):793-800. doi: 10.1056/NEJM199909093411103
15. Leizorovicz A, Cohen AT, Turpie AG, Olsson CG, Vaitkus PT, Goldhaber SZ, Group PMTS (2004) Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 110(7):874-879. doi: 10.1161/01.CIR.0000138928.83266.24
16. Cohen AT, Davidson BL, Gallus AS, Lassen MR, Prins MH, Tomkowski W, Turpie AG, Egberts JF, Lensing AW, Investigators A (2006) Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: Randomised placebo controlled trial. BMJ 332(7537):325-329. doi: 10.1136/bmj.38733.466748.7C
17. Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, Nelson ME, Wells PS, Gould MK, Dentali F, Crowther M, Kahn SR, American College of Chest P (2012) Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141(2 SUPPL.):e419S-e494S. doi: 10.1378/chest.11-2301
18. Christiaens V, Lijnen HR (2010) Angiogenesis and development of adipose tissue. Mol Cell Endocrinol 318(1-2):2-9. doi: 10.1016/j.mce.2009.08.006
19. Matsuzawa Y (2006) Therapy insight: Adipocytokines in metabolic syndrome and related cardiovascular disease. Nat Clin Pract Cardiovasc Med 3(1):35-42. doi: 10.1038/ncpcardio0380
20. Fontana L, Eagon JC, Trujillo ME, Scherer PE, Klein S (2007) Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. Diabetes 56(4):1010-1013. doi: 10.2337/db06-1656
21. Darvall KA, Sam RC, Silverman SH, Bradbury AW, Adam DJ (2007) Obesity and thrombosis. Eur J vasc endovasc surg: The official journal of the European Society for Vascular Surgery 33(2):223-233. doi: 10.1016/j.ejvs.2006.10.006
22. Sierra-Honigmann MR, Nath AK, Murakami C, Garcia-Cardena G, Papapetropoulos A, Sessa WC, Madge LA, Schechner JS, Schwabb MB, Polverini PJ, Flores-Riveros JR (1998) Biological action of leptin as an angiogenic factor. Science 281(5383):1683-1686
23. Soderberg S, Olsson T, Eliasson M, Johnson O, Ahren B (1999) Plasma leptin levels are associated with abnormal fibrinolysis in men and postmenopausal women. J Intern Med 245(5):533-543
24. Faber DR, de Groot PG, Visseren FL (2009) Role of adipose tissue in haemostasis, coagulation and fibrinolysis. Obes rev: An official journal of the International Association for the Study of Obesity 10(5):554-563. doi: 10.1111/j.1467-789X.2009.00593.x
25. Samad F, Pandey M, Loskutoff DJ (2001) Regulation of tissue factor gene expression in obesity. Blood 98(12):3353-3358
26. Lorenzet R, Napoleone E, Cutrone A, Donati MB (2012) Thrombosis and obesity: Cellular bases. Thromb Res 129(3):285-289. doi: 10.1016/j.thromres. 2011.10.021
27. Anfossi G, Russo I, Trovati M (2009) Platelet dysfunction in central obesity. Nutr Metab Cardiovasc Dis: NMCD 19(6):440-449. doi: 10.1016/j.numecd.2009.01.006
28. Cheymol G (2000) Effects of obesity on pharmacokinetics implications for drug therapy. Clin Pharmacokinet 39(3):215-231
29. Hanley MJ, Abernethy DR, Greenblatt DJ (2010) Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet 49(2):71-87. doi: 10.2165/11318100-000000000-00000
30. Summers LK, Samra JS, Humphreys SM, Morris RJ, Frayn KN (1996) Subcutaneous abdominal adipose tissue blood flow: variation within and between subjects and relationship to obesity. Clin Sci 91(6):679-683
31. Abel ED, Litwin SE, Sweeney G (2008) Cardiac remodeling in obesity. Physiol Rev 88(2):389-419. doi: 10.1152/physrev.00017.2007
32. Cheymol G (1988) Drug pharmacokinetics in the obese. Fundam Clin Pharmacol 2(3):239-256
33. Benedek IH, Fiske WD 3rd, Griffen WO, Bell RM, Blouin RA, McNamara PJ (1983) Serum alpha 1-acid glycoprotein and the binding of drugs in obesity. Br J Clin Pharmacol 16(6):751-754
34. Wasan KM, Lopez-Berestein G (1993) The influence of serum lipoproteins on the pharmacokinetics and pharmacodynamics of lipophilic drugs and drug carriers. Arch Med Res 24(4):395-401
35. Blouin RA, Kolpek JH, Mann HJ (1987) Influence of obesity on drug disposition. Clinical pharmacy 6(9):706-714
36. Brill MJ, Diepstraten J, van Rongen A, van Kralingen S, van den Anker JN, Knibbe CA (2012) Impact of obesity on drug metabolism and elimination in adults and children. Clin Pharmacokinet 51(5):277-304. doi: 10.2165/11599410- 000000000-00000
37. Buechler C, Weiss TS (2011) Does hepatic steatosis affect drug metabolizing enzymes in the liver? Curr Drug Metab 12(1):24-34
38. Pai MP (2010) Estimating the glomerular filtration rate in obese adult patients for drug dosing. Adv Chronic Kidney Dis 17(5):e53-e62. doi: 10.1053/j.ackd.2010.05.010
39. Han PY, Duffull SB, Kirkpatrick CM, Green B (2007) Dosing in obesity: A simple solution to a big problem. Clin Pharmacol Ther 82(5):505-508. doi: 10.1038/sj.clpt.6100381
40. Hainer JW, Barrett JS, Assaid CA, Fossler MJ, Cox DS, Leathers T, Leese PT (2002) Dosing in heavy-weight/obese patients with the LMWH, tinzaparin: A pharmacodynamic study. Thromb Haemost 87(5):817-823
41. Sanderink GJ, Le Liboux A, Jariwala N, Harding N, Ozoux ML, Shukla U, Montay G, Boutouyrie B, Miro A (2002) The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers. Clin Pharmacol Ther 72(3):308-318. doi: 10.1067/mcp.2002.127114
42. Rowan BO, Kuhl DA, Lee MD, Tichansky DS, Madan AK (2008) Anti-Xa levels in bariatric surgery patients receiving prophylactic enoxaparin. Obes Surg 18(2):162-166. doi: 10.1007/s11695-007-9381-y
43. Martinez L, Burnett A, Borrego M, Streeter JC, Townsend K, Garcia D (2011) Effect of fondaparinux prophylaxis on anti-factor Xa concentrations in patients with morbid obesity. Am J Health-System pharm: AJHP: official journal of the American Society of Health-System Pharmacists 68(18):1716-1722. doi: 10.2146/ajhp110010
44. Sherman DG, Albers GW, Bladin C, Fieschi C, Gabbai AA, Kase CS, O'Riordan W, Pineo GF, Investigators P (2007) The efficacy and safety of enoxaparin versus unfractionated heparin for the prevention of venous thromboembolism after acute ischaemic stroke (PREVAIL Study): An open-label randomised comparison. Lancet 369(9570):1347-1355. doi: 10.1016/S0140-6736(07)60633-3
45. Kyrle PA, Minar E, Hirschl M, Bialonczyk C, Stain M, Schneider B, Weltermann A, Speiser W, Lechner K, Eichinger S (2000) High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med 343(7):457-462. doi: 10.1056/NEJM200008173430702
46. Frederiksen SG, Hedenbro JL, Norgren L (2003) Enoxaparin effect depends on body-weight and current doses may be inadequate in obese patients. Br J surg 90(5):547-548. doi: 10.1002/bjs.4068
47. Jimenez D, Diaz G, Iglesias A, Cesar J, Garcia-Avello A, Marti D, Escobar C, Vidal R, Sueiro A (2008) Anti-factor Xa activity of enoxaparin for thromboprophylaxis in nonsurgical patients is dependent on body mass. Arch Bronconeumol 44(12):660-663
48. Bara L, Leizorovicz A, Picolet H, Samama M (1992) Correlation between anti-Xa and occurrence of thrombosis and haemorrhage in post-surgical patients treated with either Logiparin (LMWH) or unfractionated heparin Post-surgery Logiparin Study Group. Thromb res 65(4-5):641-650
49. Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos AM, Vandvik PO, American College of Chest P (2012) VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141(2 SUPPL.):e691S-e736S. doi: 10.1378/chest.11-2300
50. Nutescu EA, Spinler SA, Wittkowsky A, Dager WE (2009) Low-molecular-weight heparins in renal impairment and obesity: Available evidence and clinical practice recommendations across medical and surgical settings. Ann pharmacother 43(6):1064-1083. doi: 10.1345/aph.1L194
51. Scholten DJ, Hoedema RM, Scholten SE (2002) A comparison of two different prophylactic dose regimens of low molecular weight heparin in bariatric surgery. Obes Surg 12(1):19-24. doi: 10.1381/096089202321144522
52. Simone EP, Madan AK, Tichansky DS, Kuhl DA, Lee MD (2008) Comparison of two low-molecular-weight heparin dosing regimens for patients undergoing laparoscopic bariatric surgery. Surg Endosc 22(11):2392-2395. doi: 10.1007/s00464-008-9997-6
53. Borkgren-Okonek MJ, Hart RW, Pantano JE, Rantis PC Jr, Guske PJ, Kane JM Jr, Gordon N, Sambol NC (2008) Enoxaparin thromboprophylaxis in gastric bypass patients: Extended duration, dose stratification, and antifactor Xa activity. Surg obes Relat Dis: official journal of the American Society for Bariatric Surgery 4(5):625-631. doi: 10.1016/j.soard.2007.11.010
54. Singh K, Podolsky ER, Um S, Saba S, Saeed I, Aggarwal L, Zaya M, Castellanos A (2012) Evaluating the safety and efficacy of BMI-based preoperative administration of low-molecular-weight heparin in morbidly obese patients undergoing Roux-en-Y gastric bypass surgery. Obes Surg 22(1):47-51. doi: 10.1007/s11695-011-0397-y
55. Rondina MT, Wheeler M, Rodgers GM, Draper L, Pendleton RC (2010) Weight-based dosing of enoxaparin for VTE prophylaxis in morbidly obese, medically-Ill patients. Thromb Res 125(3):220-223. doi: 10.1016/j.thromres.2009. 02.003
56. Hamad GG, Choban PS (2005) Enoxaparin for thromboprophylaxis in morbidly obese patients undergoing bariatric surgery: findings of the prophylaxis against VTE outcomes in bariatric surgery patients receiving enoxaparin (PROBE) study. Obes Surg 15(10):1368-1374. doi: 10.1381/096089205774859245
57. Kucher N, Leizorovicz A, Vaitkus PT, Cohen AT, Turpie AG, Olsson CG, Goldhaber SZ (2005) Efficacy and safety of fixed low-dose dalteparin in preventing venous thromboembolism among obese or elderly hospitalized patients: A subgroup analysis of the PREVENT trial. Arch Intern Med 165(3):341-345. doi: 10.1001/archinte.165.3.341
58. Simoneau MD, Vachon A, Picard F (2010) Effect of prophylactic dalteparin on anti-factor Xa levels in morbidly obese patients after bariatric surgery. Obes Surg 20(4):487-491. doi: 10.1007/s11695-008-9738-x
59. Kalfarentzos F, Stavropoulou F, Yarmenitis S, Kehagias I, Karamesini M, Dimitrakopoulos A, Maniati A (2001) Prophylaxis of venous thromboembolism using two different doses of low-molecular-weight heparin (nadroparin) in bariatric surgery: A prospective randomized trial. Obes Surg 11(6):670-676. doi: 10.1381/09608920160558588
60. Nagler M, Haslauer M, Wuillemin WA (2012) Fondaparinux - data on efficacy and safety in special situations. Thromb Res 129(4):407-417. doi: 10.1016/j.thromres.2011.10.037
61. Donat F, Duret JP, Santoni A, Cariou R, Necciari J, Magnani H, de Greef R (2002) The pharmacokinetics of fondaparinux sodium in healthy volunteers. Clin Pharmacokinet 41(SUPPL. 2):1-9
62. Turpie AG, Bauer KA, Eriksson BI, Lassen MR (2002) Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: A meta-analysis of 4 randomized double-blind studies. Arch Intern Med 162(16):1833-1840
63. Turpie AG, Lassen MR, Eriksson BI, Gent M, Berkowitz SD, Misselwitz F, Bandel TJ, Homering M, Westermeier T, Kakkar AK (2011) Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies. Thromb Haemost 105(3):444-453. doi: 10.1160/TH10-09-0601
64. Mueck W, Eriksson BI, Bauer KA, Borris L, Dahl OE, Fisher WD, Gent M, Haas S, Huisman MV, Kakkar AK, Kalebo P, Kwong LM, Misselwitz F, Turpie AG (2008) Population pharmacokinetics and pharmacodynamics of rivaroxaban-an oral, direct factor Xa inhibitor-in patients undergoing major orthopaedic surgery. Clin Pharmacokinet 47(3):203-216
65. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Portman RJ (2009) Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med 361(6):594-604. doi: 10.1056/NEJMoa0810773
66. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P (2010) Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): A randomised double-blind trial. Lancet 375(9717):807-815. doi: 10.1016/S0140-6736(09)62125-5
67. Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM (2010) Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med 363(26):2487-2498. doi: 10.1056/NEJMoa1006885
68. Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G, American College of Chest P (2012) Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2 SUPPL.):e44S-e88S. doi: 10.1378/chest.11-2292
69. Wolowacz SE, Roskell NS, Plumb JM, Caprini JA, Eriksson BI (2009) Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis. Thromb haemost 101(1):77-85
70. Yee JY, Duffull SB (2000) The effect of body weight on dalteparin pharmacokinetics. A preliminary study. Eur J Clin Pharmacol 56(4):293-297
71. Garcia DA, Baglin TP, Weitz JI, Samama MM, American College of Chest P (2012) Parenteral anticoagulants: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141(2 SUPPL.):e24S-e43S. doi: 10.1378/chest.11-2291
72. Phung OJ, Kahn SR, Cook DJ, Murad MH (2011) Dosing frequency of unfractionated heparin thromboprophylaxis: A meta-analysis. Chest 140(2):374-381. doi: 10.1378/chest.10-3084
73. Raschke RA, Reilly BM, Guidry JR, Fontana JR, Srinivas S (1993) The weight-based heparin dosing nomogram compared with a "standard care" nomogram. A randomized controlled trial. Ann Intern Med 119:874-881
74. Kroon C, de Boer A, Kroon JM, Schoemaker HC, van den Meer FJ, Cohen AF (1991) Influence of skinfold thickness on heparin absorption. Lancet 337(8747):945-946
75. Quebbemann B, Akhondzadeh M, Dallal R (2005) Continuous intravenous heparin infusion prevents peri-operative thromboembolic events in bariatric surgery patients. Obes Surg 15(9):1221-1224. doi: 10.1381/096089205774512528
76. Fs M, Rosborough TK, Schwartz ML (2004) Unfractionated heparin infusion for thromboprophylaxis in highest risk gastric bypass surgery. Obes Surg 14(5):601-605. doi: 10.1381/096089204323093354